首页> 美国卫生研究院文献>Drug Design Development and Therapy >Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma

【2h】

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma

机译：CRTh2拮抗剂AZD1981作为特应性哮喘患者吸入糖皮质激素和长效β2受体激动剂的附加治疗的有效性和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectivesTo evaluate the efficacy and safety of AZD1981, a potent, specific antagonist of the CRTh2 receptor, as add-on therapy to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA), in patients with persistent asthma with an allergic component.

机译：目的评估一种有效的CRTh2受体特异性拮抗剂AZD1981作为吸入性糖皮质激素（ICS）和长效β2-激动剂（LABA）的补充疗法在持续性哮喘患者中的有效性和安全性。。

著录项

期刊名称 Drug Design Development and Therapy
作者
Eric D Bateman; Christopher O’Brien; Paul Rugman; Sally Luke; Stefan Ivanov; Mohib Uddin;
展开▼
作者单位

展开▼
年(卷),期 2018(12),-1
年度 2018
页码 1093–1106
总页数 14
原文格式 PDF
正文语种
中图分类药学;药物化学;
关键词
allergic asthma AZD1981 CRTh2 antagonist efficacy safety eosinophils;

机译：过敏性哮喘;AZD1981;CRTh2拮抗剂;疗效;安全性;嗜酸性粒细胞;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma [J] . Eric D Bateman, Christopher O’Brien, Paul Rugman, Drug Design, Development and Therapy . 2018,第InaProgress期

机译：CRTh2拮抗剂AZD1981作为特应性哮喘患者吸入性糖皮质激素和长效β2受体激动剂的附加疗法的疗效和安全性
2. TIOTROPIUM RESPIMAT (R) ADD-ON THERAPY TO INHALED CORTICOSTEROIDS (ICS) plus LONG-ACTING beta 2-AGONISTS (LABAS) IN PATIENTS WITH SYMPTOMATIC SEVERE ASTHMA: EFFICACY BY LEVEL OF AIRWAY OBSTRUCTION [J] . Frith P., Kerstjens H., Engel M., Respirology : . 2016,第Suppla2期

机译：症状重度哮喘患者的TIOTROPIUM RESPIMAT（R）补充疗法治疗吸入性糖皮质激素（ICS）和长效β2-激动剂（LABAS）：通过气道阻塞的疗效
3. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial [J] . Bleecker Eugene R., FitzGerald J. Mark, Chanez Pascal, The Lancet . 2016,第10056期

机译：苯那珠单抗对重症哮喘患者的高剂量吸入性糖皮质激素和长效β2-激动剂（SIROCCO）无法控制的有效性和安全性：一项随机，多中心，安慰剂对照的3期试验
4. Expression of surface markers on peripheral CD4<'+>CD25<'high> T cells in patients with atopic asthma: role of inhaled corticosteroid [C] . Cao Shukun, rnXu Jing, rnShi Lei, Journal of Organ Dysfunction: ISRD 2007 Abstract Book . 2007

机译：特应性哮喘患者外周血CD4'+ CD25 <'high> T细胞表面标志物的表达：吸入糖皮质激素的作用
5. Addition of leukotriene receptor antagonists versus long acting beta agonists to inhaled corticosteroid therapy for asthma treatment in older adults: A retrospective data analysis of effectiveness, safety and cost. [D] . Altawalbeh, Shoroq Mahmoud. 2015

机译：在吸入性糖皮质激素治疗中，将白三烯受体拮抗剂与长效β激动剂相比，用于老年人的哮喘治疗：有效性，安全性和成本的回顾性数据分析。
6. Montelukast as add-on therapy with inhaled corticosteroids or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial) [O] . Paul K Keith, Caroline Koch, Michel Djandji, 2009

机译：孟鲁司特作为吸入性糖皮质激素或吸入性皮质类固醇与长效β-2-激动剂的附加疗法用于诊断为哮喘和并发性变应性鼻炎的患者（RADAR试验）
7. Comparison of efficacy between long-acting beta 2-agonists (formoterol fumarate) and leukotriene-receptor antagonists (montelukast) as add-on therapy to inhaled corticosteroids (budesonide) in moderate persistent asthma [O] . Sasikala Kumaravel, Kingston Rajiah, Suchandra Sen 2014

机译：长效β2-激动剂（富马酸福莫特罗）和白三烯受体拮抗剂（孟鲁司特）作为中度持续性哮喘吸入糖皮质激素（布地奈德）的附加疗法的疗效比较

Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β2-agonists in patients with atopic asthma

摘要

著录项

相似文献

相关主题

期刊订阅